Feline Coronavirus Pathogenesis and Therapeutics

Feline coronavirus (FCoV) is widespread among domestic and wild felids, existing primarily as an enteric virus (feline enteric coronavirus, FECV) that replicates in intestinal epithelium with minimal clinical signs. Rarely, genetic mutations—particularly in the spike glycoprotein gene—enable the virus to infect monocytes and macrophages, giving rise to feline infectious peritonitis virus (FIPV). This biotype switch precipitates a systemic, immune-mediated vasculitis marked by pyogranulomatous inflammation, effusive or non-effusive disease forms and high mortality. Pathogenesis hinges on viral tropism for macrophages, dysregulated cytokine responses and lymphocyte depletion. To date, there is no fully licensed vaccine capable of preventing FIP, and traditional management has relied on supportive care. However, recent progress in antiviral drug discovery has demonstrated that protease inhibitors and nucleoside analogues can halt viral replication and reverse clinical disease. Complementary approaches using natural compounds that modulate host signalling pathways have shown promise in vitro. Meanwhile, advanced reverse genetics systems facilitate rapid generation of recombinant viruses for mechanistic studies and vaccine research. Together, these efforts offer new avenues for therapeutic intervention and a deeper understanding of coronavirus biology in companion animals, with broader implications for emerging zoonotic coronaviruses.

Research from Nature Portfolio

No recent Nature Portfolio content available.

Feline Coronavirus Pathogenesis and Therapeutics publication trend

The graph below shows the total number of articles in feline coronavirus pathogenesis and therapeutics across all publications each year (not limited to Nature Index journals).

Technical terms

Feline enteric coronavirus (FECV): The avirulent biotype of FCoV that replicates in intestinal epithelial cells, typically causing subclinical or mild enteritis.

Feline infectious peritonitis virus (FIPV): A mutated biotype of FCoV that infects macrophages, triggering a fatal systemic inflammatory disease known as feline infectious peritonitis.

Macrophage tropism: The capacity of a virus to preferentially infect and replicate within macrophages, facilitating systemic dissemination and immunopathology.

Reverse genetics: A molecular technique that constructs recombinant viruses from cloned cDNA to dissect gene function and pathogenesis, and to aid vaccine development.

Nucleoside analogue: An antiviral compound structurally similar to natural nucleosides that inhibits viral RNA polymerase, thereby blocking genome replication.

References

1. Baicalin Inhibits FIPV Infection In Vitro by Modulating the PI3K-AKT Pathway and Apoptosis Pathway. International Journal of Molecular Sciences (2024).
2. Development of a rapid reverse genetics system for feline coronavirus based on TAR cloning in yeast. Frontiers in Microbiology (2023).
3. Reversal of the Progression of Fatal Coronavirus Infection in Cats by a Broad-Spectrum Coronavirus Protease Inhibitor. PLOS Pathogens (2016).
4. Curing Cats with Feline Infectious Peritonitis with an Oral Multi-Component Drug Containing GS-441524. Viruses (2021).